Skip to main content

Table 1 Advanced stage ovarian cancer cohort, demographic characteristics and healthcare utilization (N=12,659)

From: A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer

Characteristics N (%)
Total advanced incident cancer cases from January 1, 2010 to January 31, 2018 (N, %)a,b  
Advanced stage at diagnosis, N (%)c 12,237 (96.67%)
Diagnosed as early stage and progressed to advanced stage, N (%) 422 (3.33%)
Age (years)
 Mean (SD) 61.94 (14)
 Q1 53
 Median 62
 Q3 72
Region
 Midwest 3436 (28.48%)
 Northeast 2293 (19.01%)
 South 2976 (24.67%)
 West 3358 (27.84%)
Year of index date
 2010-2011 4712 (37.22%)
 2012-2014 4468 (35.30%)
 2015-2018 3479 (27.48%)
Plan type
 Commercial 9288 (73.37%)
 Medicare Advantage 1511 (11.94%)
 Medicare, Other 1860 (14.69%)
Duration of health plan membership prior to advanced stage index date (months)
 Mean (SD) 48.16 (28.25)
 Q1 23.24
 Median 48.20
 Q3 68.86
Duration of follow-up (months)
 Mean (SD) 24.52 (23.28)
 Q1 6.47
 Median 17.25
 Q3 35.19
Deyo-Charlson Comorbidity Index (DCI) during follow-up
 Mean (SD) 6.34 (2.63)
 Q1 5
 Median 6
 Q3 8
Number of drugs dispensed during follow-up
 Mean (SD) 12.61 (9.76)
 Q1 5
 Median 11
 Q3 18
  1. Abbreviations: N Number, SD Standard deviation, US United States, Q Quartile, ED Emergency department.
  2. aThe cohort includes patients who had at least one ICD-9-CM or ICD-10 diagnosis code for ovarian cancer, were continuously enrolled in a health plan contributing data to the HIRD for at least six months, and were confirmed to have advanced ovarian cancer based on staging information from either a cancer registry or the HIRE Oncology data or met the predictive model algorithm for advanced stage ovarian cancer.
  3. bIncident cases are individuals for whom at least six months of data were available in the HIRD prior to the first diagnosis of ovarian cancer in claims.
  4. cCases are defined as "advanced stage at diagnosis" if their advanced stage date (from cancer registry, HIRE Oncology, or predictive model) was within one month of their first cancer diagnosis in claims, otherwise they are defined as "Diagnosed as early stage and progressed to advanced stage".